January 19, 2022
Via: Contract PharmaAkari Therapeutics, Plc, a late-stage biopharmaceutical company focused on therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, has announced that the U.S. Food and Drug Administration ( FDA ) has agreed, […]
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
September 14, 2023
August 30, 2023
September 20, 2023